Prof. Dr. Leendert Trouw

Brief summary of research:

During my career, I have continuously focused on complement and (auto)antibodies. In my PhD-studies I became fascinated by the pathological consequences of complement and autoantibodies and was the first to show the pathogenicity of anti-C1q autoantibodies (J.Clin.Invest.2004). My post-doc studies in Sweden, revealed the importance of complement-inhibitors binding to free-DNA and dead cells (J.Exp.Med.2005). Subsequently, I choose to work (supported by a Veni-grant) in the Dept. of Rheumatology, LUMC, to implement obtained knowledge on complement and autoantibodies in a clinical setting. Several autoantibodies are known in Rheumatoid Arthritis but in 2011, with my team, I discovered a new autoantibody recognizing carbamylated-proteins (Proc.Natl.Acad.Sci.2011). During the last five years, using my Vidi-grant, I have unravelled the anti-CarP antibody response in depth and observed that they are present years before disease onset and are associated with development of RA and with disease severity. The predictive, diagnostic and prognostic properties have now been replicated in several international studies and following patenting, a commercial test is now being developed. How autoantibodies contribute to arthritis is still unknown, but I have demonstrated the complement activating potential of RA-associated antibodies. With my ERC-grant, we study the role of complement in autoantibody responses develop against modified self-proteins. In addition, I planned to use my expertise in complement and autoantibodies to develop modified-autoantibodies as therapeutics. Therefore, I have moved my group from the Rheumatology to the Immuno-Haematology (LUMC), one of the top Dutch immunology departments focusing on multiple disease areas, allowing a broad implementation of our findings.


Curriculum Vitae:

I studied Biology at Leiden University, specialising in Medical Biology and graduated in 1999. I did my PhD training with Prof. Daha at the Department of Nephrology at the Leiden University Medical Center and defended my thesis entitled ‘Pathologic significance of autoantibodies against C1q in the development of nephritis’  in 2004.


Current and previous positions:

2017-present    Associate Professor, Dept. of Immunology, LUMC, Leiden

2016-2017        Associate Professor, Dept. of Rheumatology, LUMC, Leiden

2012-2016        Assistant Professor, Dept. of Rheumatology, LUMC, Leiden

2007-2012        Postdoc, Dept. of Rheumatology, LUMC, Leiden

2004-2007        Postdoc, Dept. of Clinical Chemistry, Lund University, Malmö, Sweden



  • Circulating Levels of Anti-C1q and Anti-Factor H Autoantibodies and Their Targets in Normal Pregnancy and Preeclampsia

    Dijkstra DJ, Lokki AI, Gierman LM, Borggreven NV, van der Keur C, Eikmans M, Gelderman KA, Laivuori H; FINNPEC Core Investigator Group; Iversen AC, van der Hoorn MP, Trouw LA.

    Front Immunol. 2022 Mar 31;13:842451.

  • Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations

    Monahan RC, van den Beukel MD, Borggreven NV, Fronczek R, Huizinga TWJ, Kloppenburg M, Steup-Beekman GM, Trouw LA.

    RMD Open. 2022 Apr;8(1):e002079.

  • Carbamylation reduces the capacity of IgG for hexamerization and complement activation.

    Verheul MK, Janssen GMC, de Ru A, Stoeken-Rijsbergen G, Levarht EWN, Kwekkeboom JC, Bomer N, Ioan-Facsinay A, Meulenbelt I, Cordfunke RA, Drijfhout JW, Toes REM, van Veelen PA, Trouw LA

    Clin Exp Immunol. 2020 Apr;200(1):1-11.

Collaborate with us

Looking for information on one of our topics, a new place to conduct your research or connect to experienced researchers to join forces with?  Feel free to contact us!

Read more